Literature DB >> 2877847

Sulphasalazine: a review of 40 years' experience.

G Watkinson.   

Abstract

Sulphasalazine, devised by Dr Nana Svartz for the treatment of 'infective polyarthritis', has been used in the treatment of inflammatory bowel disease for more than 40 years. Many controlled trials have shown that sulphasalazine 4g daily will induce remissions in between one-half and three-quarters of patients with acute attacks of ulcerative colitis. When given in a dosage of 2g daily it will prevent relapses in quiescent colitis. Relapses are 5 times more likely in untreated patients. It is less effective in Crohn's disease, where it exerts only a transient benefit in patients with active colonic disease and fails to prevent relapse or recurrence. Sulphasalazine is absorbed from the small intestine, re-excreted in bile and carried to the colon, where its azo bond is split by bacteria to release sulphapyridine, which is absorbed and is responsible for most of the drug's side effects, and 5-aminosalicylic acid, which is the active therapeutic moiety of the drug and exerts a beneficial topical action on the colonic mucosa. Side effects are common but are mainly reversible and not serious. Those related to high concentrations of sulphapyridine and to poor acetylation of the drug include gastrointestinal intolerance, malaise, headache, arthralgia, drug fever, effects on red blood cells and reversible male infertility. More serious, idiosyncratic side effects are skin rashes, leucopenia and agranulocytosis. Rarely, neurotoxicity, hepatotoxicity, polyarteritis, pulmonary fibrosis, a lupus-like syndrome and haemorrhagic colitis are produced. It is possible to desensitise most patients with drug-induced skin rashes. A number of less toxic alternatives to sulphasalazine have been devised and are undergoing trial. They either convey 5-aminosalicylic acid in a coated tablet to the colon or, when conjugated to a non-toxic carrier, release 5-aminosalicylic acid by bacterial cleavage there. Sulphasalazine remains a most useful drug in the treatment of inflammatory bowel disease after 40 years of use.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2877847     DOI: 10.2165/00003495-198600321-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  44 in total

1.  Heinz-body anaemia due to salicylazosulphapyridine.

Authors:  A I SPRIGGS; R S SMITH; H GRIFFITH; S C TRUELOVE
Journal:  Lancet       Date:  1958-05-17       Impact factor: 79.321

2.  Red cell abnormalities associated with sulphasalazine maintenance therapy for ulcerative colitis.

Authors:  R E Pounder; E R Craven; J S Henthorn; J M Bannatyne
Journal:  Gut       Date:  1975-03       Impact factor: 23.059

3.  The long-term prophylactic effect of salazosulphapyridine (Salazopyrin) in primarily resected patients with Crohn's disease. A controlled double-blind trial.

Authors:  A Wenckert; M Kristensen; A E Eklund; F Barany; S Jarnum; H Worning; O Folkenborg; A Holtz; O Bonnevie; P Riis
Journal:  Scand J Gastroenterol       Date:  1978       Impact factor: 2.423

4.  Azulfidine agranulocytosis with bone marrow, megakaryocytosis, histiocytosis and plasmacytosis.

Authors:  K Jamshidi; T Arlander; M C Garcia; H W Windschitl; W R Swaim
Journal:  Minn Med       Date:  1972-06

Review 5.  The medical treatment of ulcerative colitis.

Authors:  G Watkinson
Journal:  Postgrad Med J       Date:  1968-09       Impact factor: 2.401

6.  Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease.

Authors:  B I Korelitz; D H Present; P H Rubin; S E Fochios
Journal:  J Clin Gastroenterol       Date:  1984-02       Impact factor: 3.062

7.  On the efficacy of ready-made-up commercially available salicylazosulphapyridine enemas in the treatment of proctitis, proctosigmoiditis and ulcerative colitis involving rectum, sigmoid and descending colon.

Authors:  P Frühmorgen; L Demling
Journal:  Hepatogastroenterology       Date:  1980-12

8.  Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  N Engl J Med       Date:  1973-09-06       Impact factor: 91.245

9.  Sulphasalazine and male infertility: reversibility and possible mechanism.

Authors:  S Toovey; E Hudson; W F Hendry; A J Levi
Journal:  Gut       Date:  1981-06       Impact factor: 23.059

10.  The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.

Authors:  K M Das; M A Eastwood; J P McManus; W Sircus
Journal:  Gut       Date:  1973-08       Impact factor: 23.059

View more
  12 in total

1.  Fraction of theophylline in sustained-release formulation which is absorbed from the large bowel.

Authors:  D K Sommers; E C Meyer; M van Wyk; J Moncrieff
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Prophylactic and therapeutic effects of oral budesonide for acute radiation-induced enteritis and colitis in rats.

Authors:  Mehmet Odabasi; Suleyman Gokdemir; Tolga Muftuoglu; Ali Aktekin; Abdullah Saglam; Fugen Aker
Journal:  Int J Clin Exp Med       Date:  2014-04-15

Review 3.  Drug toxicity.

Authors:  H A Bird
Journal:  Ann Rheum Dis       Date:  1990-05       Impact factor: 19.103

4.  High fever induced by sulphasalazine.

Authors:  S D Hearing; S Playfor; S J Bentley
Journal:  BMJ       Date:  1995-11-04

5.  Drug Management in the Elderly IBD Patient.

Authors:  Marina Kim; Seymour Katz; Jesse Green
Journal:  Curr Treat Options Gastroenterol       Date:  2015-03

Review 6.  Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs.

Authors:  J E Keeble; P K Moore
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

Review 7.  Neurological disorders and inflammatory bowel diseases.

Authors:  Giovanni Casella; Gian Eugenio Tontini; Gabrio Bassotti; Luca Pastorelli; Vincenzo Villanacci; Luisa Spina; Vittorio Baldini; Maurizio Vecchi
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

8.  Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group.

Authors:  S Kiilerich; K Ladefoged; T Rannem; P J Ranløv
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

Review 9.  [Neurological complications of inflammatory bowel diseases].

Authors:  N Cieplik; M Stangel; O Bachmann
Journal:  Nervenarzt       Date:  2013-02       Impact factor: 1.214

10.  Olsalazine versus placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial.

Authors:  G E Feurle; D Theuer; S Velasco; B A Barry; D Wördehoff; A Sommer; G Jantschek; W Kruis
Journal:  Gut       Date:  1989-10       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.